NATiV3
85 evidence topics · 26 sources
Objective
Primary objectives of Part A and Part B in the ClinicalTrials.gov record
Key secondary and other secondary objectives in the ClinicalTrials.gov record
Main objective in the EU Clinical Trials Information System record
Aim of the trial stated by the company in September 2026
Primary objectives of Part 1 and Part 2 in the original ClinicalTrials.gov record, April 2021, superseded in March 2023
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2021-08-19” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-09-29” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09-30” (opens the source at this quote in a new tab)
“First Posted 2021-04-19” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-02” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record
Activation of the first sites in the United States, September 2021
Sites, countries, and regional distribution of randomized participants, December 2023
Initiation, sites in Ukraine and Russia, China participation, and completion of screening and randomization stated in the Form 20-F
Last patient visit of the 72-week treatment period, September 2026
Estimated completion dates in the ClinicalTrials.gov record, January 2023, superseded in March 2023
Study design
Official title and design details in the ClinicalTrials.gov record
Trial phase and transition status in the EU Clinical Trials Information System record
Main cohort, exploratory cohort, and active treatment extension in the company design slide
“Noncirrhotic MASH and F2-F3 fibrosis” (opens the source at this quote in a new tab)
“Screen-failed patients from the main cohort” (opens the source at this quote in a new tab)
“noncirrhotic MASH and F1-F4 fibrosis” (opens the source at this quote in a new tab)
“Stratification by fibrosis stage and diabetic status” (opens the source at this quote in a new tab)
Randomization ratio, stratification factors, and amended design stated by the company
Active treatment extension described as double-blind in the registry records
Extension described as open-label by the company in September 2026
Exploratory cohort of participants histologically not eligible for the main cohort
Central biopsy review process developed with regulatory authorities
January 2023 protocol amendments replacing Part 2 with a separate outcomes trial in compensated cirrhosis
Amended design posted in the ClinicalTrials.gov record, March 2023
Two-part design with a Part 2 clinical outcomes period in about 2,000 participants, January 2021, superseded in January 2023
Part 2 clinical outcome primary measure in the ClinicalTrials.gov record, January 2023, superseded in March 2023
Eligibility criteria
Prescreening criteria in the ClinicalTrials.gov record
Liver-related exclusion criteria in the ClinicalTrials.gov record
Glycemic, obesity-related, cardiovascular, and general exclusion criteria in the ClinicalTrials.gov record
“HbA1c >9% at Screening” (opens the source at this quote in a new tab)
“Diabetes mellitus other than type 2” (opens the source at this quote in a new tab)
“Current treatment with insulin” (opens the source at this quote in a new tab)
“Atrial fibrillation requiring anticoagulation” (opens the source at this quote in a new tab)
Concomitant GLP-1 receptor agonist allowed at a stable dose, company design slide
Exclusion of autoimmune liver or thyroid disease added after a suspected unexpected serious adverse reaction, February 2024
Treatment
Treatment arms and tablets in the ClinicalTrials.gov record
Randomization to two lanifibranor doses or placebo stated by the company
Treatment duration of the main and exploratory cohorts and the extension, company design slide
Active treatment with lanifibranor for all participants during the 48-week extension
Liver monitoring every 6 weeks added for enrolled participants, March 2024
Study outcomes
Rationale for using MASH resolution and fibrosis improvement of at least one stage as the primary endpoint
Primary outcome measure as named and defined in the ClinicalTrials.gov record
Primary endpoint as a composite and the two single histologic endpoints as key secondary endpoints, company wording
“Primary end point:” (opens the source at this quote in a new tab)
“Key secondary end points:” (opens the source at this quote in a new tab)
Single histologic endpoints named key primary or key secondary endpoints in the company's financing terms
Primary outcome measure titled resolution of NASH in the original ClinicalTrials.gov record, April 2021, superseded in October 2021
Composite endpoint carried over from the phase 2b NATIVE trial
Phase 2b effect on the composite endpoint by type 2 diabetes status cited for NATiV3
FDA draft guidance: histologic endpoints reasonably likely to predict clinical benefit for accelerated approval
FDA draft guidance: confirmatory outcome trials underway at submission and the composite clinical endpoint
EMA reflection paper: two composite histologic endpoints required as co-primary endpoints for conditional approval
Regulatory consultation before the trial: accelerated and conditional approval on the 72-week histology analysis
Accelerated approval on histologic endpoints and confirmation in a separate outcomes trial after the January 2023 amendments
Precedent: accelerated approval of resmetirom based on the two single histologic endpoints
Reliability of NASH CRN histologic scoring between readers in a phase 2 trial
“Inter-reader linearly weighted kappas were 0.609, 0.484, 0.328, and 0.517 for steatosis, fibrosis, lobular inflammation, and ballooning, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inter-reader unweighted kappas were 0.400 for the diagnosis of NASH, 0.396 for NASH resolution without worsening fibrosis, and 0.366 for fibrosis improvement without worsening NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Simulations show that the lack of reliability of endpoints and inclusion criteria can drastically reduce study power - from >90% in a well-powered study to as low as 40%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EMA reflection paper: observer variability of the NASH CRN system and centralized reading by at least two histopathologists
Digital versus glass slide reading of NATiV3 screening biopsies, AASLD 2025 poster
Validation of whole slide images against glass slides for steatohepatitis scoring in clinical trials
“The results from this validation study support the conclusion that the WSI IMS platform is equivalent to the glass read in reference to a robust glass GT when used by pathologists to evaluate steatohepatitis trial populations for diagnosis and trial‐based scoring criteria and histologic feature scoring during enrollment and for follow‐up timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA statements on noninvasive biomarkers as replacements for liver biopsy
Noninvasive tests in the exploratory cohort
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the ClinicalTrials.gov record
Enrollment targets and participants randomized in the main and exploratory cohorts, April 2025
Statistical power for the sample size calculation and enrollment, company design slide
Participants planned for the histologic analysis supporting the NDA, Form 20-F
Estimated enrollment of 2000 in the ClinicalTrials.gov record, April 2021, superseded in March 2023
Planned histology analysis in about 900 participants, January 2021, superseded in April 2025
Planned exploratory cohort of about 200 participants, December 2023, superseded in April 2025
Description of analysis sets
Analysis periods for the Part B safety analyses in the ClinicalTrials.gov record
Histologic analysis population and exploratory cohort contribution to the safety database, Form 20-F
Results
Participant disposition
Completion of randomization in the main and exploratory cohorts and the drop-out condition, April 2025
Completion of the 72-week treatment period by all participants, September 2026
Participants remaining to complete the 72-week biopsy, October 2025
Randomized participants, screening, and screen failure rate, December 2023
Participants randomized before the voluntary screening pause, February 2024
Treatment duration of participants at the fifth Data Monitoring Committee review, October 2024
Screen failure rate and enrollment delays stated in the Form 20-F
Baseline characteristics
Demographic and metabolic characteristics of the NATiV3 main cohort compared with NATIVE, company slides
| Characteristic | NATiV3 (main cohort) | NATIVE |
|---|---|---|
| Participants | “NATiV3 N=1009” | “NATIVE N=247” |
| Female | “59%” | “58%” |
| Male | “41%” | “42%” |
| Weight (kg), mean (SD) | “97.10”; “(± 23.6)” | “93.30”; “(± 18.8)” |
| BMI class obese (30 or more) | “75%” | “65%” |
| Type 2 diabetes | “55%” | “42%” |
| HOMA-IR, mean (SD) | “9.8”; “(± 10.2)” | “10.1”; “(± 12.7)” |
| HbA1c, mean (SD) | “6.5%”; “(± 1.0)” | “6.0%”; “(± 0.7)” |
| Adiponectin (µg/mL), mean (SD) | “4.6”; “(± 2.7)” | “5.1”; “(± 2.7)” |
“median: NATiV3 = 95kg | NATIVE = 92kg” (opens the source at this quote in a new tab)
“median: NATiV3 = 7.3 | NATIVE = 6.7” (opens the source at this quote in a new tab)
“median: NATiV3 = 6.2% | NATIVE = 5.9%” (opens the source at this quote in a new tab)
“median: NATiV3 = 4.0 | NATIVE = 4.5” (opens the source at this quote in a new tab)
Liver disease characteristics of the NATiV3 main cohort compared with NATIVE, company slides
| Characteristic | NATiV3 (main cohort) | NATIVE |
|---|---|---|
| Fibrosis stage F2 | “33.0%” | “41.3%” |
| Fibrosis stage F3 | “67.0%” | “34.8%” |
| Liver stiffness measurement (kPa), median | “10.1” | “8.9” |
| Controlled attenuation parameter (dB/m), median | “329” | “327” |
| ALT (U/L), median | “50” | “51” |
| AST (U/L), median | “40” | “37” |
| FIB-4 score, median | “1.35” | “1.19” |
| ELF score, median | “9.6” | “9.7” |
“mean ±SD: NATiV3 = 324 ± 48 | NATIVE = 327.7 ± 43.2” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 59 ± 36 | NATIVE = 62 ± 39” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 47 ± 26 | NATIVE = 47 ± 32” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 9.7 ± 0.9 | NATIVE = 9.7 ± 1.0” (opens the source at this quote in a new tab)
Concomitant SGLT2 inhibitor and GLP-1 receptor agonist use at baseline in the NATiV3 main cohort compared with NATIVE, company slides
Interim baseline characteristics of participants randomized in the main cohort, December 2023
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, February 2024
Other milder aminotransferase elevations among trial participants, Form 20-F
Recovery of the participant with the suspected unexpected serious adverse reaction, May 2024
Third Data Monitoring Committee review of blinded safety data, December 2023
Fourth Data Monitoring Committee review of unblinded safety data, May 2024
Fifth Data Monitoring Committee review of unblinded safety data, October 2024
Study limitations
Summary: results not yet reported and blinded safety information
The ClinicalTrials.gov record gives an actual primary completion date of 2026-09-29 and an estimated study completion date of 2027-09-30. All participants had completed the 72-week treatment period, and Inventiva expected to report topline results in the fourth quarter of 2026. The safety information available comes from company statements on Data Monitoring Committee reviews: one review used safety data from more than 500 participants, including participants treated with lanifibranor for more than 72 weeks; another used unblinded data from more than 900 participants randomized in the main and exploratory cohorts; and at another the data were unblinded to the committee and remained blinded with respect to the company.
Summary: histologic surrogate endpoint, endpoint naming, and reader variability
- The primary outcome is histologic: resolution of NASH and improvement of fibrosis at week 72, defined by NASH CRN scores for ballooning of 0, inflammation of 0 to 1, and a fibrosis decrease of at least 1 stage. Inventiva states that accelerated approval and conditional authorization, even if granted, require completion of the trial to obtain full approval.
- The January 2023 protocol amendments replaced the planned Part 2 of NATiV3, a clinical outcome trial in approximately 2,000 participants with F2 and F3 fibrosis for a maximum of seven years, with a separate event-driven phase 3 outcome trial in participants with compensated cirrhosis. The Form 20-F states that the FDA's guidance during a consultation preceding the amendments was to continue NATiV3 as originally planned, and that the FDA did not object to the amendments.
- Sources name the endpoints differently. The ClinicalTrials.gov record names the composite of NASH resolution and fibrosis improvement as the primary outcome, and the investor and analyst day presentation names the composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints. The financing terms in the Form 20-F describe the two single endpoints as “key primary endpoint or key secondary endpoint”. The original registry version (April 2021) titled the primary measure "Resolution of NASH" while defining it as the composite. Efficacy for the accelerated approval of resmetirom was determined on the two single endpoints, and the EMA reflection paper states that efficacy for both endpoints (resolution of NASH and improvement of fibrosis by at least 1 stage) should be demonstrated in co-primary fashion.
- Davison et al. reported inter-reader unweighted kappas of 0.396 for NASH resolution without worsening fibrosis and 0.366 for fibrosis improvement without worsening NASH, and simulations in which unreliable endpoints and inclusion criteria reduced study power from >90% to as low as 40%.
Summary: enrollment figures, protocol amendments, and the extension period
- Enrollment figures differ by source and date. The ClinicalTrials.gov record gives an estimated enrollment of 1000 (2000 in the April 2021 version). Inventiva reports 1,009 participants in the main cohort and 410 in the exploratory cohort, exceeding the original targets of 969 and 350. The Form 20-F anticipates an NDA based on histologic endpoints in approximately 950 patients, and the NATiV3 design release planned the histology analysis in approximately 900 patients.
- The January 2023 amendments reduced the number of biopsies per participant from three to two and the trial duration a participant consents to from 7 years to 72 weeks. In 2022, recruitment was put on hold in Ukraine and all planned sites in Russia were removed.
- A treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, with biopsy results compatible with autoimmune hepatitis, led to a voluntary pause in screening and randomization, an amendment excluding newly screened patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. Before the pause, 913 participants had been randomized, including 731 in the main cohort.
- The ClinicalTrials.gov and EU Clinical Trials Information System records describe the 48-week Part B extension as double-blind; the company's last patient visit release describes it as open-label, with all participants, including those originally randomized to placebo, receiving lanifibranor.
Summary: enrolled population and generalizability
- Inventiva reported a recent screen failure rate of approximately 80% in December 2023, and the Form 20-F states that a higher than originally projected screen failure rate slowed enrollment.
- The main cohort differs from the NATIVE population in company slides: type 2 diabetes 55% versus 42%, fibrosis stage F3 67.0% versus 34.8%, obesity 75% versus 65%, GLP-1 receptor agonist use at baseline 14.0% versus 0.0%, and SGLT2 inhibitor use 10.0% versus 2.8%.
- As of December 2023, approximately 70% of participants randomized in the main and exploratory cohorts were from the United States, approximately 20% from Europe, and approximately 10% from Latin America and the rest of the world.
- Exclusion criteria include HbA1c >9% at screening, current insulin treatment, history of heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, current approved treatment for NASH or obesity, thiazolidinedione treatment in the prior 12 months, and hemoglobin <11 g/dL in females or <12 g/dL in males.